Eocene Announces its First European Sales and Distribution Agreement to Accelerate the Commercialization of Colospan's CG-100 Device
Key Highlights
- ➤Eocene (EOCN) signs first European distribution agreement for CG-100
- ➤Hospital Line receives exclusive CG-100 marketing and distribution rights in Greece and Cyprus
- ➤CG-100 launch in Greece and Cyprus planned alongside Colospan’s ongoing U.S. pivotal study
- ➤Colospan plans to launch CG-100 at the 17th Hellenic-Cypriot Surgical Conference
Expert Statements
Allen Baharaff, President and Chief Executive Officer of Eocene
“CG-100 was developed to address one of the greatest challenges in colorectal surgery by providing a potential alternative to diverting stomas. Signing our first European commercial distribution agreement represents an important milestone for Colospan. We look forward to introducing CG-100 together with Hospital Line and to supporting clinicians in a new approach that we believe could reduce the need for stomas for colorectal cancer patients.”
Boaz Assaf, Founder and Chief Executive Officer of Colospan
“We are very pleased to partner with Hospital Line, an established medical device distributor with strong relationships across the surgical communities in Greece and Cyprus. This agreement marks an important step in our European commercialization strategy, and we believe Hospital Line is well positioned to support the adoption of CG-100 in these markets. We are particularly excited to officially launch CG-100 at the upcoming 17th Hellenic-Cypriot Surgical Conference, which we believe will provide an excellent opportunity to introduce our innovative technology to leading surgeons and demonstrate its potential to transform colorectal surgery by reducing the need for diverting stomas.”
Anargyros Karellas, Chief Executive Officer of Hospital Line SA
“We are delighted to establish this partnership with Colospan and to introduce CG-100 to the Greek and Cypriot markets. We believe this innovative technology addresses a significant unmet clinical need in colorectal surgery and has the potential to improve patient care while reducing the burden associated with diverting stomas. We are looking forward to working closely with Colospan and the surgical community to bring this technology into clinical practice.”
Eocene Announces its First European Sales and Distribution Agreement to Accelerate the Commercialization of Colospan's CG-100 Device PR Newswire
GIVATAYIM, Israel, Nov. 10, 2026 /PRNewswire/ -- Eocene Ltd. (NASDAQ: EOCN) ("Eocene" or the "Company") today announced that its wholly owned subsidiary, Colospan Ltd. ("Colospan"), has entered into its first European commercial distribution agreement for its CG-100 device with Hospital Line SA ("Hospital Line"). Under the agreement, Hospital Line has been granted exclusive rights to market, sell and distribute CG-100 in Greece and Cyprus. Colospan intends for the agreement to serve as a foundation for the potential further commercial expansion of CG-100 into additional European markets. The planned commercial launch of CG-100 in Greece and Cyprus is expected to proceed in parallel with Colospan's ongoing U.S. pivotal study of CG-100.
Get started
Create a free account to read the full story.